Abstract Library

#4103 The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

Introduction: Tumor evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumors (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease.

Conference:

Presenting Author: Crona J

Authors: Backman S, Botling J, Nord H, Ghosal S, Stålberg P,

Keywords: Pancreatic neuroendocrine tumor, Tumor evolution, Alkylating chemotherapy, Treatment resistance,

#3735 Longitudinal changes in Ki-67 index in a prospective cohort of pancreatic neuroendocrine tumors

Introduction: The biology of pancreatic neuroendocrine tumors (panNET) can change over time. In retrospective cohorts, many panNETs showed longitudinal increases in Ki-67 index leading to a higher tumor grade and poor survival. However, data from prospective studies are lacking, and non-invasive methods of determining tumor grade progression are needed in order to monitor and guide further treatment.

Conference:

Presenting Author: Mollazadegan K

Authors: Mollazadegan K, Botling J, Welin S, Zhang L, Eriksson B,

Keywords: neuroendocrine tumor, pancreas, high-grade, poor prognosis, biomarker, Ki-67,

#2822 Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors

Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mollazadegan K, Botling J, Welin S, Eriksson B, Skogseid B,

Keywords: pancreas, neuroendocrine tumor, treatment,